LAUSR

of myeloperoxidase, CD34, and CD117. Blood tests To the Editor: The presence of FIP-1-like-1-platelet-derived growth factor receptor-a (FIP1L1-PDGFRA, F/P) fusion identified the presence of eosinophilia (3.86 10/L, 49.2% gene accounts for approximately 23% (3%–56%) of all eosinophilias. From 2008, the World Health Organization (WHO) classification redefined this disease as “myeloid/lymphoid neoplasms with eosinophilia and PDGFRA rearrangement,” now constituting a distinct type of hematopoietic disorders. F/P fusion is a tyrosine kinase and is therefore sensitive to tyrosinekinase inhibitors (TKIs). TKIs are recommended as the first-line therapy in the treatment of myeloid/lymphoid neoplasms with eosinophilia and PDGFRA rearrangement by the WHO guidelines.